Coherus Oncology, Inc. Restructuring Charges
Coherus Oncology, Inc. (CHRS) reported Restructuring Charges of $3.60 million for the 12-month period ending 2017-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2020-02-27
- Coherus Oncology, Inc. restructuring charges for fiscal 2017 was $3.60M.
| Period end | Restructuring Charges 1 month | Restructuring Charges 12 month |
|---|---|---|
| 2017-12-31 | $3.60M 10-K · filed 2020-02-27 | |
| 2017-06-30 | $3.60M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |